Intermittent Androgen Deprivation for Clinically Localized Prostate Cancer: Initial Experience-Reference-Cited by-同舟云学术

Intermittent Androgen Deprivation for Clinically Localized Prostate Cancer: Initial Experience

Published:1998-01 Issue:1 Volume:51 Page:137-144
ISSN:0090-4295
Container-title:Urology
language:en
Short-container-title:Urology

Author:

Grossfeld Gary D,Small Eric J,Carroll Peter R

Publisher

Elsevier BV

Subject

Urology

Reference17 articles.

1. Cancer statistics, 1996;Parker;CA Cancer J Clin,1996

2. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening;Catalona;JAMA,1993

3. Osteoporosis after orchiectomy for prostate cancer;Daniell;J Urol,1997

4. Bone fractures associated with luteinizing hormone-releasing hormone agonists used in the treatment of prostate carcinoma;Townsend;Cancer,1997

5. Anemia associated with androgen deprivation (AAAD) due to combination hormone blockade (CHB) responds to recombinant human erythropoietin (r hu-EPO) (abstract);Strum;J Urol,1997

Cited by 66 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Norcantharidin induces mitochondrial-dependent apoptosis through Mcl-1 inhibition in human prostate cancer cells;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2017-10

2. Conversion to monotherapy with luteinizing-hormone releasing hormone agonist or orchiectomy after reaching PSA nadir following maximal androgen blockade is able to prolong progression-free survival in patients with metastatic prostate cancer: A propensity score matching analysis;Oncology Letters;2017-04-20

3. Intermittent androgen deprivation in prostate cancer cases with biochemical progression after radical prostatectomy: Are we ready to treat?;Critical Reviews in Oncology/Hematology;2016-03

4. The Role of Intermittent Androgen Deprivation Therapy in the Management of Biochemically Recurrent or Metastatic Prostate Cancer;Current Urology Reports;2015-02-13

5. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis;BMC Urology;2014-01-25